Mizuho downgraded Adaptimmune (ADAP) to Neutral from Outperform with a 50c price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune’s Annual Meeting Focuses on Shareholder Engagement
- Hold Rating for Adaptimmune Therapeutics Amid Strategic Progress and Financial Uncertainties
- Biotech Alert: Searches spiking for these stocks today
- Adaptimmune’s Earnings Call: Success Amid Financial Concerns
- Cautious Hold on Adaptimmune Therapeutics Amid Strategic Developments and Liquidity Concerns